- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT07946549
A Study to Evaluate the Safety and Efficacy of CID-103 in Adults With Chronic Immune Thrombocytopenia
A Dose-escalation and Safety Study of CID-103 Followed by a Randomized, Open-label, Parallel-arm Multi-dose Study Evaluating the Efficacy and Tolerability of CID-103 in Adults With Chronic Immune Thrombocytopenia
The goal of the global Phase 1/2 clinical trial is to evaluate whether CID-103, a novel anti-CD38 monoclonal antibody, is safe and effective in adults with chronic immune thrombocytopenia (ITP). The main questions the study aims to answer are:
- To evaluate the safety and tolerability of CID-103 in subjects with ITP with different increasing doses of CID-103.
- To further evaluate the safety and tolerability of CID-103 at two or three dose levels and to select an optimal dose and administration regimen for CID-103 for further study of clinical efficacy.
The study will be done in two parts:
Part A will test increasing doses of CID-103 to see how safe it is and how well people tolerate it. Researchers will also aim to find a safe dose range.
Part B will compare up to three different doses of CID-103 to see how well the medicine works and gather more safety and efficacy information. The goal is to find the optimal dose to use in future studies.
CID-103 is given through an intravenous (IV) infusion. During the study, participants may receive treatment for up to 6 months, followed by a post-treatment safety follow-up period to check for ongoing safety and effectiveness.This study is an important step toward developing a new treatment for people living with chronic ITP. If CID-103 is found to be safe and effective, it could offer a new option for patients who do not respond well to current therapies.
Visão geral do estudo
Status
Condições
Intervenção / Tratamento
Descrição detalhada
The enrollment of participants in part A has been completed (ClinicalTrials.gov ID: NCT07017725). Totally 23 participants have been enrolled. Three CID-103 doseages including 600mg, 900mg, and 1200mg have been proposed for part B for further evaluation.
This is Part B study, it will compare 600mg, 900mg, and 1200mg doses of CID-103 to see how well the medicine works and gather more safety and efficacy information. The goal is to find the optimal dose to use in future studies.
Tipo de estudo
Inscrição (Estimado)
Estágio
- Fase 2
Contactos e Locais
Contato de estudo
- Nome: Aaron Yang
- Número de telefone: +86 10 6561 8789
- E-mail: aarony@casi.cn
Estude backup de contato
- Nome: Hao Zhang
- Número de telefone: +86 10 6561 8789
- E-mail: haoz@casi.cn
Locais de estudo
-
-
Beijing Municipality
-
Beijing, Beijing Municipality, China, 100000
- Peking Union Medical College Hospital
-
Contato:
- Tienan Zhu
- Número de telefone: +86 10 69151188
- E-mail: zhutn@pumch.cn
-
-
Guangdong
-
Guangzhou, Guangdong, China, 510000
- Nanfang Hospital, Southern Medical University
-
Contato:
- Jieyu Ye
- Número de telefone: +86 20 61641888
- E-mail: jieyu_ye@163.com
-
-
Hebei
-
Tangshan, Hebei, China, 063000
- North China University of Science and Technology Affiliated Hospital
-
-
Henan
-
Zhengzhou, Henan, China, 450000
- Henan Cancer Hospital
-
-
Hubei
-
Wuhan, Hubei, China, 430000
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
-
Contato:
- Heng Mei
- Número de telefone: +86 27 85726114
- E-mail: hmei@hust.edu.cn
-
-
Jiangsu
-
Suzhou, Jiangsu, China, 215000
- The First Affiliated Hospital of Soochow University
-
Contato:
- Jie Yin
- Número de telefone: +86 512 65223637
- E-mail: yinjie@suda.edu.cn
-
-
Jiangxi
-
Nanchang, Jiangxi, China, 330000
- The First Affiliated Hospital of Nanchang University
-
-
Shaanxi
-
Xi'an, Shaanxi, China, 710000
- Shaanxi Provincial People's Hospital
-
Contato:
- Yi Wang
- Número de telefone: +86 29 85251331
- E-mail: 13571936193@163.com
-
-
Shandong
-
Jinan, Shandong, China, 50000
- Qilu Hospital of Shandong University
-
-
Tianjin Municipality
-
Tianjin, Tianjin Municipality, China, 300000
- Institute of Hematology & Blood Diseases Hospital, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences
-
Contato:
- Lei Zhang
- Número de telefone: +86 22 23909999
- E-mail: zhanglei1@ihcams.ac.cn
-
-
Yunnan
-
Kunming, Yunnan, China, 650000
- The Second Affiliated Hospital of Kunming Medical University
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Descrição
Inclusion Criteria:
-
Male or female individuals aged 18 to 65 years at time of signing of ICF.
-
Diagnosed with ITP that has persisted for ≥ 3 months, diagnosed in accordance with The American Society of Hematology 2019 Guidelines for Immune Thrombocytopenia or the Updated International Consensus Report on the Investigation and Management of Primary Immune Thrombocytopenia (as locally applicable).
-
Diagnosis of ITP supported by a prior response to an ITP treatment (other than a thrombopoietin receptor agonists [TPO-RA]) that achieved a platelet count of ≥ 30 x 10^9/L and a doubling of baseline measurement.
-
Has received at least two lines of SOC systemic treatment (i.e., corticosteroids and one other agent).
Note: Subjects who have received one line of treatment and who are currently receiving a second line of treatment are also considered eligible Exceptions: Subjects who are intolerant of SOC treatment or subjects who do not have access to SOC treatment; approval from Medical Monitor is required.
-
Has a mean platelet count ≤ 35 x 10^9/L on at least two measurements at least one week apart during screening.
-
If receiving standard background treatment for ITP, treatment should be stable in dose and frequency for at least four weeks prior to first dose of CID-103.
Note: Permitted standard background treatments for ITP may include:
- one oral corticosteroid with or without up to two of the following
- one immunosuppressant from the following list: azathioprine, danazol, dapsone, cyclosporine, mycophenolate mofetil, mycophenolate sodium
- one TPO-RA (romiplostim, eltrombopag, avatrombopag) administered at standard therapeutic doses for at least four weeks
- fostamatinib.
-
Adequate organ function
-
Contraception: Female participants must either be non-pregnant or not breastfeeding and must have a negative pregnancy test. Male and female participants must meet the contraceptive requirements.
Exclusion Criteria:
-
Prior treatment with any anti-CD38 agent, or has been treated with anti-Bruton's tyrosine kinase (BTK), neonatal Fc receptor (FcRn) antagonist or complement inhibitor within three months prior to first dose of CID-103.
-
Use of intravenous (IV) immunoglobulin, subcutaneous immunoglobulin or anti-D immunoglobulin treatment within four weeks of screening.
-
IgG < 300 mg/dL
-
Use or expected immediate use of rescue therapy for an active hemorrhage, high risk of bleeding or critically low platelets within two weeks prior to first dose of CID-103.
-
More than a 10% variation in corticosteroid and/or TPO-RA dose within two weeks prior to first dose of CID-103
-
Treatment with rituximab or splenectomy within the three months prior to first dose of CID-103.
-
Use of anticoagulants or any drug with antiplatelet effect (such as aspirin) within three weeks before screening.
-
Immunosuppressant drugs other than corticosteroids and those outlined in inclusion criterion #6.
Note: These drugs should be discontinued for at least 14 days before first dose of CID-103.
-
Receiving other concurrent investigational therapies or have received investigational therapies within four weeks of the first dose of CID-103 or five half-lives (if shorter).
-
Active hemolytic anemia.
-
Diagnosed with severe chronic obstructive pulmonary disease (COPD), Global Initiative for Chronic Obstructive Lung Disease (GOLD Stage 3 or 4) or asthma, and a pre-bronchodilator forced expiratory volume in one second (FEV1) < 50% of predicted normal.
-
Has been diagnosed with myelodysplastic syndrome or other active malignancy.
-
Known / clinically significant amyloidosis.
-
Requires renal dialysis.
-
Has a history of any thrombotic or embolic event within six months before screening.
-
A history or evidence of cardiovascular risk including any of the following:
- Current left ventricular ejection fraction < 50%
- A history or evidence of current clinically significant uncontrolled ventricular arrhythmia. Subjects with atrial fibrillation controlled for > 30 days prior to first dose of CID-103 are eligible.
- A history of acute coronary syndrome (including myocardial infarction or unstable angina), coronary angioplasty or stenting within six months prior to first dose of CID-103
- A history or evidence of current ≥ Class III congestive heart failure as defined by the New York Heart Association (NYHA) guidelines
- Treatment refractory hypertension defined as a blood pressure of systolic > 160 mmHg and/or diastolic > 100 mmHg which cannot be controlled by anti-hypertensives.
-
History or clinical evidence of any surgical or medical condition which the Investigator judges as likely to interfere with the results of the study or pose an additional risk in participating, particularly any pre-existing condition that would put the subject at additional risk should they experience an IRR
-
Any unresolved treatment-related AE(s) from prior treatment that have not resolved to Grade 1 or baseline value prior to first dose of CID-103.
-
Active infection requiring systemic therapy.
-
Known hypersensitivity to CID-103 excipients or prior severe hypersensitivity to a monoclonal antibody.
-
History of severe recurrent or chronic infections, or acute infections requiring systemic treatment with antibiotics, antiviral drugs, antiparasitic drugs, anti-amoebic drugs, or antifungal drugs within four weeks prior to the first dose of CID-103 and during the screening period, or superficial skin infections requiring systemic treatment within one week prior to the first dose of CID-103.
-
History of known or suspected immunosuppression, including invasive opportunistic infections such as histoplasmosis, listeriosis, coccidioidomycosis, pneumocystis pneumonia, and aspergillosis, even if the infection has resolved; or unusually frequent, recurrent, or prolonged infections (as judged by the Investigator).
-
Known active infection with human immunodeficiency virus (HIV) and CD4+ T cell count < 350/μL.
-
Known active infection with hepatitis B (HBV) (surface antigen) or infection with hepatitis C (HCV) in absence of sustained virologic response.
-
At the time of signing informed consent is a regular user (including "recreational / medical use") of any illicit drugs or had a recent history (within the last year) of substance abuse (including alcohol). If a subject agrees to abstain for the duration of the study and is for a month prior to first dose of CID 103, they may be considered for enrollment in the trial at the discretion of the Investigator in agreement with the Medical Monitor.
-
Karnofsky Performance Status ≤ 70
-
Inability to perform study baseline RBC type and cross-match, phenotype (and genotype, if applicable) or lack of available baseline data on RBC phenotype (or genotype, if applicable).
-
Unable or not willing to agree to the evaluation of RBC antigens by phenotyping or genotyping.
-
Unable or not willing to sign the ICF and comply with the protocol and the restrictions and assessments therein.
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Tratamento
- Alocação: Randomizado
- Modelo Intervencional: Atribuição Paralela
- Mascaramento: Nenhum (rótulo aberto)
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
|---|---|
|
Experimental: CID-103 1200mg
Following an initial priming dose of 150 mg on Week 1, participants will receive CID-103 at dose 1200mg administered. |
Strength:20 mg/mL. Route of administration: IV infusion. Treatment duration: QW for 6 weeks, then at the same dose Q2W up to Week 12. If treatment continues after Week 12, dosing will occur monthly for up to a maximum treatment duration of 6 months. |
|
Experimental: CID-103 900mg
Following an initial priming dose of 150 mg on Week 1, participants will receive CID-103 at dose 900mg administered. |
Strength:20 mg/mL. Route of administration: IV infusion. Treatment duration: QW for 6 weeks, then at the same dose Q2W up to Week 12. If treatment continues after Week 12, dosing will occur monthly for up to a maximum treatment duration of 6 months. |
|
Experimental: CID-103 600mg
Following an initial priming dose of 150 mg on Week 1, participants will receive CID-103 at dose 600mg administered. |
Strength:20 mg/mL. Route of administration: IV infusion. Treatment duration: QW for 6 weeks, then at the same dose Q2W up to Week 12. If treatment continues after Week 12, dosing will occur monthly for up to a maximum treatment duration of 6 months. |
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Safety and tolerability of CID-103, Frequency of TEAEs
Prazo: 10 months
|
Frequency of TEAEs |
10 months
|
|
Safety and tolerability of CID-103, Related AEs
Prazo: 10 months
|
Related AEs |
10 months
|
|
Safety and tolerability of CID-103, Grade 3/4 AEs
Prazo: 10 months
|
Grade 3/4 AEs |
10 months
|
|
Safety and tolerability of CID-103, Serious adverse events (SAEs)
Prazo: 10 months
|
Serious adverse events (SAEs) |
10 months
|
|
Safety and tolerability of CID-103, Fatal AEs
Prazo: 10 months
|
Fatal AEs |
10 months
|
|
Safety and tolerability of CID-103, AEs leading to CID-103 discontinuation
Prazo: 12 weeks
|
AEs leading to CID-103 discontinuation up to Week 12 |
12 weeks
|
|
Safety and tolerability of CID-103
Prazo: 12 weeks
|
Percentage of participants with at least one treatment-related Grade ≥ 3 TEAE, SAE or AE leading to CID-103 discontinuation up to Week 12 |
12 weeks
|
|
Platelet response
Prazo: 12 weeks
|
A platelet count ≥ 50 x 10^9/L and ≥ 20 x 10^9/L above baseline achieved on at least two consecutive measurements at least seven days apart. |
12 weeks
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Platelet count
Prazo: 12 weeks
|
The secondary efficacy endpoint is Platelet count, defined as platelet count ≥ 30 x 10^9/L and > 2-fold increase in platelet count from baseline and absence of bleeding requiring medical intervention / treatment, measured on at least two consecutive occasions at least seven days apart. |
12 weeks
|
|
Complete platelet response
Prazo: 12 weeks
|
The secondary efficacy endpoint includes percentage of participants with complete platelet response, defined as platelet count ≥ 100 x 10^9/L and absence of bleeding requiring medical intervention / treatment, measured on at least two consecutive occasions at least seven days apart. |
12 weeks
|
Colaboradores e Investigadores
Patrocinador
Colaboradores
Investigadores
- Cadeira de estudo: Junping Chen, CASI pharmaceuticals, Inc.
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Estimado)
Conclusão Primária (Estimado)
Conclusão do estudo (Estimado)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Palavras-chave
Outros números de identificação do estudo
- XY2024067-EC-4
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .